Dashboard
Poor Management Efficiency with a low ROE of 0.67%
- The company has been able to generate a Return on Equity (avg) of 0.67% signifying low profitability per unit of shareholders funds
Poor long term growth as Net Sales has grown by an annual rate of 12.38% over the last 5 years
Positive results in Jun 25
Risky - Negative EBITDA
High Institutional Holdings at 27.81%
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 77 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.75
-10.70%
2.41
Total Returns (Price + Dividend) 
Sol-Gel Technologies Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Sol-Gel Technologies Hits New 52-Week High of $30.98, Surges 3861%
Sol-Gel Technologies achieved a new 52-week high of USD 30.98 on September 19, 2025, reflecting a remarkable performance in the Pharmaceuticals & Biotechnology sector. The company reported a 1574.2% increase in net sales to USD 18.29 million in the first half of the year, despite ongoing losses.
Read MoreIs Sol-Gel Technologies Ltd. technically bullish or bearish?
As of 4 September 2025, the technical trend for Sol-Gel Technologies Ltd. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. However, the monthly RSI is bearish, suggesting some weakness in price strength. The daily moving averages are bullish, supporting the overall positive outlook. Despite the bullish trend, the weekly OBV is mildly bearish, which could indicate some selling pressure. In terms of performance, the stock has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 185.64% compared to the S&P 500's 12.22%, and a one-year return of 310.25% versus 17.14%. Overall, the current technical stance is bullish, with strong momentum indicators but some caution due to the bearish monthly RSI....
Read MoreIs Sol-Gel Technologies Ltd. overvalued or undervalued?
As of 10 March 2023, the valuation grade for Sol-Gel Technologies Ltd. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.00 and an EV to Sales ratio of 0.30, which suggest limited growth potential in relation to its market price. Additionally, the company's negative ROCE of -388.12% and ROE of -64.66% further highlight its struggles in generating returns for shareholders. In comparison to its peers, Sol-Gel Technologies Ltd. has a significantly higher EV to EBITDA ratio of -11.1084 compared to Assembly Biosciences, Inc. at -6.6467 and Societal CDMO, Inc. at 18.7985, indicating that it is not performing well relative to its industry counterparts. The overall financial health and performance metrics suggest that the company is overvalued in the current market context. The...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Foreign Institutions
Held in 2 Schemes (0.12%)
Held by 8 Foreign Institutions (17.75%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 1,630.00% vs 233.33% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 231.82% vs -51.72% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 618.75% vs -58.97% in Dec 2023
YoY Growth in year ended Dec 2024 is 61.03% vs -82.55% in Dec 2023






